Cosmo Pharmaceuticals saw the highest growth of 10.99% in patent filings in May and 1.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.24% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Cosmo Pharmaceuticals’s patent filings and grants. Buy the databook here.
Cosmo Pharmaceuticals has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 15% filings and 50% grants. The Argentina(AR), United States(US), Israel(IL), and Australia(AU) patent Office are among the top ten patent offices where Cosmo Pharmaceuticals is filings its patents. Among the top granted patent authorities, Cosmo Pharmaceuticals has 50% of its grants in United States(US) and 25% in Israel(IL).
Roche could be the strongest competitor for Cosmo Pharmaceuticals
Patents related to artificial intelligence and healthtech lead Cosmo Pharmaceuticals's portfolio
Cosmo Pharmaceuticals has the highest number of patents in artificial intelligence followed by, healthtech and data science. For artificial intelligence, nearly 24% of patents were filed and no patents were granted in Q2 2024.
Image management related patents lead Cosmo Pharmaceuticals portfolio followed by digital signal processors(dsp), and mos micro (mpu, mcu & dsp)
Cosmo Pharmaceuticals has highest number of patents in image management followed by digital signal processors(dsp), mos micro (mpu, mcu & dsp), pouchitis, and healthcare it.
For comprehensive analysis of Cosmo Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.